Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00290407 · ClinicalTrials.gov registry record · Phase 2
Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)
A Phase 2 study, sponsored by University of Louisville.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT00290407 is a Phase 2 study that was terminated before completion, run by University of Louisville. The registered enrollment target is 2 participants.
The verdict
NCT00290407, a Phase 2 study, was terminated before completion, sponsored by University of Louisville.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to determine how well subjects respond to treatment with Rituximab plus Beta-Glucan.
Interventions
- DRUG Rituximab
- DIETARY_SUPPLEMENT Beta-Glucan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2006-03 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00290407
The ClinicalTrials.gov registry entry for NCT00290407 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Louisville, which has 217 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rituximab is the first listed.
NCT00290407 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00290407 about?
NCT00290407 is a clinical study titled "Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)". The purpose of this study is to determine how well subjects respond to treatment with Rituximab plus Beta-Glucan.
What is the current status of trial NCT00290407?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2006-03. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00290407?
The interventions under investigation include: Rituximab (DRUG), Beta-Glucan (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00290407?
This trial is sponsored by University of Louisville, which has 217 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.